Peoples Financial Services CORP. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 5.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,018 shares of the company’s stock after selling 1,650 shares during the period. Johnson & Johnson makes up 2.1% of Peoples Financial Services CORP.’s portfolio, making the stock its 9th largest holding. Peoples Financial Services CORP.’s holdings in Johnson & Johnson were worth $3,744,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Stuart Chaussee & Associates Inc. lifted its holdings in Johnson & Johnson by 20.7% during the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 80 shares in the last quarter. Selective Wealth Management acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $105,000. Ifrah Financial Services Inc. acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $203,000. Exane Asset Management acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $206,000. Finally, Peak Capital Management LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $207,000. Institutional investors own 67.32% of the company’s stock.
Several analysts recently commented on the stock. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target for the company in a research report on Wednesday, March 27th. BMO Capital Markets increased their price objective on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday. Raymond James increased their price objective on shares of Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Citigroup raised their price target on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research report on Monday, February 25th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $146.40.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a return on equity of 35.79% and a net margin of 17.99%. The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same period in the previous year, the business posted $2.06 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current year.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.